Our CEO, Immanuel Lerner will be visiting Singapore, and attending the J-Labs Singapore Family Office Investor Event.
In addition to attending the J-Labs Singapore Family Office Investor Event, he will be in Singapore from September 14-17 for additional meetings with collaborators in the peptide therapeutics space.
Pepticom joins Johnson & Johnson’s global incubator network JLABS EMEA & Singapore, as a virtual member company
Pepticom Ltd. is proud to be a virtual member company of Johnson & Johnson‘s global incubator network, JLABS, in EMEA and Singapore. JLABS is the largest global network of open innovation ecosystems, enabling and empowering emerging companies with the knowledge, experience, partnerships, and venture connections across a broad healthcare spectrum including pharmaceutical and medical technology […]
Our CEO Immanuel Lerner will be attending & presenting at the NextGen Biomed 2025 in London, March 12-13
Join our CEO, Immanuel Lerner for insights on AI-driven peptide drug discovery:📅 March 12:🗝 Keynote – Orally Available Peptides | 9:55 AM💡 Panel – Novel Peptide Therapeutics | 12:30 PM 📅 March 13:🎙 Moderator – Optimizing Drug Candidates | 2:15 PM
Our CEO and co-founder, Dr. Immanuel Lerner and our Advisory Board Member, Dr. Sarah Benson-Konforty will attend the J.P. Morgan Global Healthcare Conference
Join them at the J.P. Morgan 43rd Annual Healthcare Conference 2025, which will take place 13-16 January 2025 in San Francisco, CA, USA.Mr. Lerner will also participate in the Executive Roundtable Wuxi Global Forum, and host a table on Jan 14th from 5-6pm PST. You can reserve a spot here >> https://lnkd.in/d6qhfYWi
Our CEO Immanuel Lerner will be presenting at the DDIF 15th Annual Drug Discovery Innovation Forum in Berlin on September 5th
Our CEO Immanuel Lerner has been selected to speak at the #DDIF 15th Annual Drug Discovery Innovation Forum in Berlin, on September 4-5, 2024!
Our COO Maayan Elias Robicsek will attend Biomed Israel 2025, May 21-23/2024
Our COO Maayan Elias Robicsek is attending Biomed Israel 2025! Come and say hello to learn about our AI drug discovery platform
Dr. Sarah Benson-Konforty joining the Board of Directors and Executive Committee of the AAIH
Pepticom is excited to be taking an active role in shaping the future of AI in healthcare — Congratulations to Dr. Sarah Benson-Konforty, MD for joining the Board of Directors and Executive Committee of the The Alliance for Artificial Intelligence in Healthcare (AAIH)Â
Visit us at BIOMED Israel May 16-18
Join us at booth #3 in the Start-Up Pavilion on May 16th, at BIOMED 2023, Israel’s largest life sciences conference.
“Exploration Science” episode hosting our CEO Immanuel Lerner, and Head of Research, Amit Michaeli
Dr. Wendy Hartsock hosted our CEO, Immanuel Lerner, and Head of Research, Amit Michaeli on an episode of CEM Corporation‘s “Exploration Science”. They discussed the advantages of employing biocomputational AI to accelerate peptide discovery.You can tune in to the whole interview here:Youtube: http://ow.ly/SkgW50NPnmvSpotify: http://ow.ly/YTON50NPo0S
Pepticom joined The Alliance for Artificial Intelligence in Healthcare (AAIH)
The AAIH is a coalition of technology developers, pharmaceutical companies, and research organizations who share our goal of leveraging #AI to advance the quality of healthcare, with a special focus on AI-guided pharmaceutical development.Our advisor, Sarah Benson-Konforty, will attend our first AAIH Annual Members Meeting this May 17-18th in San Francisco.